Insight Molecular Diagnostics Inc. (IMDX)
(Delayed Data from NSDQ)
$3.08 USD
-0.19 (-5.81%)
Updated Sep 23, 2025 02:27 PM ET
3-Hold of 5 3
F Value B Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IMDX 3.08 -0.19(-5.81%)
Will IMDX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IMDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMDX
3 Medical Info Systems Stocks to Buy Amid AI Boom and Tariff Risk
IMDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for IMDX
NR7 appears for IMDX after 4.11% move
Pocket Pivot appears for IMDX after 1.19% move
Is IMDX primed for upward momentum? Upper Bollinger Band Walk shows up after gaining 1.81%
Insight Molecular Diagnostics Approves Executive Salary Increases
Is IMDX preparing to trend higher? New Uptrend shows up after slipping 3.78%